AWM
CRSP icon

Apollon Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Apollon Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$455K Buy
8,350
+543
+7% +$28.6K 0.01% 1062
2026
Q1 		$371K Buy
7,807
+175
+2% +$9.23K 0.01% 999
2025
Q4 		$400K Buy
7,632
+747
+11% +$44.7K 0.01% 926
2025
Q3 		$446K Buy
+6,885
New +$395K 0.01% 872
2022
Q1 		– Sell
-5,259
Closed -$399K – 775
2021
Q4 		$399K Buy
+5,259
New +$459K 0.03% 513

Other funds holding CRSP

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SC
Slow Capital Greenbrae, California $857M AUM 38.3% 1-Year Est. Return
CIC
Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $900M AUM
BIP
Bouvel Investment Partners Phoenixville, Pennsylvania $442M AUM 70.77% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
LIM
Leavell Investment Management Mobile, Alabama $2.74B AUM 26.51% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Apollon Wealth Management's CRSP Position: Q2 2026 in Review

Apollon Wealth Management increased its CRISPR Therapeutics (CRSP) stake by 7% in Q2 2026, buying an estimated $28.6K and bringing the position to 8,350 shares worth $455K. The position accounts for 0.01% of the portfolio, ranked #1062.

Apollon Wealth Management first reported a position in CRSP in Q4 2021 and has held it in 5 quarters since. 92 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Apollon Wealth Management held 8,350 shares of CRISPR Therapeutics worth $455K as of Q2 2026.
  • Apollon Wealth Management bought 543 CRISPR Therapeutics shares in Q2 2026, an estimated $28.6K.
  • CRISPR Therapeutics made up 0.01% of Apollon Wealth Management's portfolio in Q2 2026, its #1062 holding.
  • Apollon Wealth Management first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 5 quarters since.
  • 92 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Apollon Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.